Alnylam European Patent Upheld by Opposition Board
July 16, 2009
Alnylam European Patent Upheld by Opposition Board
The patent includes claims covering methods of silencing about 130 genes using siRNAs of up to 49 nucleotides in length and had been challenged by Merck subsidiary Sirna Therapeutics, according to Alnylam.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Silence Responds to Alnylam European Patent Claims
March 15, 2012 / Gene Silencing News - Novartis, Alcon Join Alnylam in Opposing Silence Patent in Europe
July 28, 2011 / Gene Silencing News - Alnylam Files Opposition Against Silence Patent in Europe
November 18, 2010 / Gene Silencing News - EPO to Award Alnylam Patent on Use of RNAi Molecules in Cancer
September 10, 2009 / Gene Silencing News - Tuschl-I Patent Upheld in Europe
March 8, 2012 / Gene Silencing News